University of Oulu

Sioofy‐Khojine A‐B, Lehtonen JP, Nurminen N, et al. HLA‐DQ‐conferred risk for type 1 diabetes does not alter neutralizing antibody response to a widely used enterovirus vaccine, the poliovirus vaccine. J Med Virol. 2023;95:e28707. doi:10.1002/jmv.28707

HLA‐DQ‐conferred risk for type 1 diabetes does not alter neutralizing antibody response to a widely used enterovirus vaccine, the poliovirus vaccine

Saved in:
Author: Sioofy‐Khojine, Amir‐Babak1; Lehtonen, Jussi P.1; Nurminen, Noora1;
Organizations: 1Department of Virology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
2Department of Paediatrics, Turku University Hospital, Turku, Finland
3Faculty of Medicine, Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, Turku, Finland
4Department for Children and Adolescents, Oulu University Hospital, Oulu, Finland
5Department of Paediatrics, MRC Oulu, University of Oulu, Oulu, Finland
6Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland
7Department of Clinical Microbiology, Turku University Hospital, Turku, Finland
8Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland
9Pediatric Research Centre, New Children's Hospital, Helsinki University Hospital, Helsinki, Finland
10Tampere Centre for Child Health Research, Tampere University Hospital, Tampere, Finland
11Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 1.5 MB)
Persistent link:
Language: English
Published: John Wiley & Sons, 2023
Publish Date: 2023-09-07


This study investigated whether children with HLA-DQ-conferred risk for type 1 diabetes (T1D) have an altered immune response to the widely-used enterovirus vaccine, namely poliovirus vaccine, and whether initiation of autoimmunity to pancreatic islets modulates this response. Neutralizing antibodies induced by the inactivated poliovirus vaccine against poliovirus type 1 (Salk) were analysed as a marker of protective immunity at the age of 18 months in a prospective birth cohort. No differences were observed in antibody titers between children with and without genetic risk for T1D (odds ratio [OR] = 0.90 [0.83, 1.06], p = 0.30). In the presence of the genetic risk, no difference was observed between children with and without islet autoimmunity (OR = 1.00 [0.78, 1.28], p = 1.00). This did not change when only children with the autoimmunity before 18 months of age were included in the analyses (OR = 1.00 [0.85, 1.18], p = 1.00). No effect was observed when groups were stratified based on autoantigen specificity of the first-appearing autoantibody (IAA or GADA). The children in each comparison group were matched for sex, calendar year and month of birth, and municipality. Accordingly, we found no indication that children who are at risk to develop islet autoimmunity would have a compromised humoral immune response which could have increased their susceptibility for enterovirus infections. In addition, the proper immune response supports the idea of testing novel enterovirus vaccines for the prevention of T1D among these individuals.

see all

Series: Journal of medical virology
ISSN: 0146-6615
ISSN-E: 1096-9071
ISSN-L: 0146-6615
Volume: 95
Issue: 4
Article number: e28707
DOI: 10.1002/jmv.28707
Type of Publication: A1 Journal article – refereed
Field of Science: 3121 General medicine, internal medicine and other clinical medicine
Funding: This study was funded by—The Leona M. and Harry B. Helmsley Charitable Trust (Heikki Hyöty; Grant No. 2010-04139), the Academy of Finland (Heikki Hyöty; Grant No. 288671), Sigrid Juselius Foundation (Heikki Hyöty), Novo Nordisk Foundation (Heikki Hyöty; Grant No. NNF18OC0034080), Reino Lahtikari Foundation (Heikki Hyöty), Päivikki and Sakari Sohlberg's Foundation grant (Jutta E. Laiho), and the European Commission (Heikki Hyöty; Persistent Virus Infection in Diabetes Network [PEVNET] Frame Program 7, Contract No. 261441). DIPP study has additionally been funded by the Competitive Research Funding of the University Hospitals in Tampere, Oulu and Turku.
Dataset Reference: The data that support the findings of this study are available on request from the corresponding author upon reasonable request. The data are not publicly available due to privacy or ethical restrictions.
Copyright information: © 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.